Case report : We present an unusual case of recurrent and bilateral multiple evanescent white dot syndrome (MEWDS), who had three bilateral episodes in a period of nine years. Thirteen years after the first episode, she was diagnosed with subretinal neovascularization (SRNV) which showed a satisfactory response to photodynamic therapy, with a final visual acuity of 20/40. Discussion: MEWDS is considered classically to be an inflammatory disease with a good visual prognosis. Although the development of SRNV is unusual, we recommend long term follow-up of these patients since the early diagnosis and treatment of SRNV are both relevant for the retention of visual acuity (Arch Soc Esp Oftalmol 2007; 82: 587-590).
INTRODUCTION
The multiple evanescent white dot syndrome (MEWDS) is defined as an entity whose clinical progression is self-limited, benign, of unknown etiology and rarely recurrent. Nevertheless, the severe loss of vision secondary to a choroidal neovascularization has been described in the literature (1, 2) . The present case presumably involves a recurrent MEWDS that developed a subretinal neovascular membrane (SRNV) thirteen years after the initial episode.
CASE REPORT
In January 1992, a 36-year-old emetropic female arrived in our emergency unit reporting blurry vision without any previous flu episode. Exploration revealed 20/30 visual acuity (VA) in the right eye (RE) and 20/60 in the left eye (LE), 1+ cells in the anterior chamber for both eyes (BE) and 100-200 micra multiple white dots, more abundant in the macula's temporal area in BE. The fluorescein angiography (FAG) showed multiple hyperfluorescent dots (figs. 1 and 2). Treatment began with 40 mg per day of IM methylprednisolone (Urbason ® soluble 40 mg, Aventis Pharma S.A., Madrid), 10 mg/ml of topical atropine sulphate (1% Atropina ® , Alcon Cusí S.A., Barcelona) every 12 hours and 1 mg/ml topical dexamethasone (Maxidex ® , Alcon Cusí S.A., Barcelona) every 6 hours. After administering treatment for two weeks, VA reached 20/20 in BE. The requested systemic tests (basic blood testing, chest x-rays, luetic serology, angiotensinconverting enzyme and Mantoux) were negative.
Four years later, the patient had a new relapse, more marked in the RE, with loss of vision of 20/60 in the RE and 20/30 in the LE, yet showing no visual field alterations. The same systemic pattern seen in the previous episode emerged, with full visual recovery after one month of treatment, although some white dots persisted together with the upper temporal peripapillary pigment in the RE.
In September 2001, a new outbreak occurred, although slighter in nature. VA stood at 20/25 in the RE and 20/20 in the LE, while funduscopic examination revealed white-yellowish dots spread across the posterior pole and alteration of the macular retinal pigment epithelium (RPE) in BE. As in the first episode, treatment included topical and systemic corticoids. Three weeks after the onset of the new outbreak, VA decreased to 20/40 in the RE and 20/60 in the LE, which led to adding oral metotrexate (Metotrexato Lederle ® , Whyeth, Madrid) at low doses. The requested HLA A29 study turned out negative.
In Currently, the patient's VA is 20/40 in the RE and 20/25 in the LE, with faded white-yellowish dots in the anterior pole of both eyes, lesions related to a peripapillary atrophy in BE, involving the papillary-macular bean in the RE and several whitish, inactive lesions below the macula in the LE (fig. 6 ).
DISCUSSION
MEWDS is a rare ocular inflammatory disease of unknown etiology that tends to affect young women and is usually characterized by a self-limited progression, spontaneous recovery of visual acuity in 3 to 10 weeks and minimal sequelae in the RPE (1) (2) (3) (4) (5) .
In the present case, three episodes were reported during 9 years, all of them bilateral. This clinical pattern of MEWDS presentation (bilateral and recurrent) is extremely unusual, not knowing the reason why some patients progress differently than others (2, 3) .
We found at least five cases described in the literature concerning SRNV in patients suffering from MEWDS (table I) . In the present case, SRNV developed 13 years after the first MEWDS outbreak, with a final VA of 20/40.
During the progression of a recurrent MEWDS, the confluence of inflammatory areas and the persistence of inflammation may lead to chorioretinal scars (4). Our patient developed areas of peripapillary atrophy and several white-yellowish, atrophic lesions in areas of previous inflammatory activity. These alterations at the RPE level may predispose to the development of SRNV.
In the present case, the recurrent episodes of this disease where brought under control with low doses of metotrexate. Cyclosporine was also successfully used to achieve remission of outbreaks (3).
Our patient did not present vitritis, cystic macular aedema, papillary aedema, or the peripheral chorioretinal lesions that characterize multifocal choroiditis (MFC). Furthermore, she was emetropic, thus discarding a punctate inner choroidopathy. On the other hand, Kozielec et al (4) located near the papilla, in the posterior pole and mid-periphery resembling MFC lesions and presumed ocular histoplasmosis, although the scarring pattern is different. All of the above leads one to think of a probably atypical MEWDS. Bryan et al (5) describe a series of cases with previous MEWDS or after MFC where there is likely a susceptibility, etiology and/or pathogenesis common to these two clinical entities, even though this fact remains unknown.
Despite the good visual prognosis for patients suffering from MEWDS, we believe these patients should be assessed in the long term due to the risk of developing SRNV. 
